Table 6 Comparison between the percentage of major adverse effect between enhancement and non-enhancement groups in study
| Non-enhancement | Enhancement | p value | |
|---|---|---|---|
| Major adverse effect | |||
| No | 14 (87.5%) | 3 (20%) | *p ≤0.001 |
| Yes | 2 (12.5%) | 12 (80%) | |
| Non-enhancement | Enhancement | p value | |
|---|---|---|---|
| Major adverse effect | |||
| No | 14 (87.5%) | 3 (20%) | *p ≤0.001 |
| Yes | 2 (12.5%) | 12 (80%) | |